PharmSource – CMO Scorecard: Outsourcing of NDA Approvals and CMO Performance – 2017 Edition

2017-04-01
Price :
Published : Apr-2017
No. of Pages : 42

PharmSource – CMO Scorecard: Outsourcing of NDA Approvals and CMO Performance – 2017 Edition

Summary

PharmSource’s data-rich Trend Report, CMO Scorecard: Outsourcing of NDA Approvals and CMO Performance – 2017 Edition, has ascertained that 2016 was not a halcyon year for new drug approvals with only 25 NMEs being approved since 2010.

Global bio/pharma companies received 22 approvals in 2016 (24% of all NDAs), 10% below their 2011-2015 average. Small commercial companies were responsible for 21 approvals (23% of the total), some 5% above their five-year average. There was a clear difference between outsourcing propensity of NME and Non-NME drugs. Only 13% of NMEs sponsored by global bio/pharma com¬panies were outsourced compared with an average of 28% from 2011-2015. However, the largest companies increased their outsourcing of Non-NME drugs from an average of 32% in 2011-2015 to 57% in 2016.

In 2016, the FDA approved 92 NDAs and BLAs including new molecular entities (NMEs), therapeutic drugs approved through CBER and new formulations of older drugs. This figure represents a 25% decrease from 2015 (122) and is also 5% less than the 2011-2015 average of 97. Furthermore, 48% of NMEs were outsourced compared to 64% of Non-NME NDA products. 28 dose CMOs garnered approvals in 2016 although two companies, Vetter and Patheon, won 7 out of the 12 NMEs that were outsourced. No other company secured more than a single NME approval for contract manufacturing, although Catalent and DPT were responsible for 7 Non-NME NDA drugs.

The CMO landscape is dominated by the quartet of Patheon, Baxter, Vetter and Catalent, which collec¬tively accounted for over 30% of all NDA approvals between 2007-2016. Parenteral NME outsourcing is dominated by the first three of these, which are responsible for manufacturing 47% of all drugs, with the remainder split between 28 other companies.

The report “PharmSource – CMO Scorecard: Outsourcing of NDA Approvals and CMO Performance – 2017 Edition” analyzes the performance of the drug product CMO industry using NDA approvals as the primary indicator of performance. The report examines 91 drugs approved by the FDA Center for Drug Evaluation and Research (CDER) in 2016 along with 1 therapeutic drug approved by the FDA Center for Biolog-ics Evaluation and Research (CBER) under the BLA process.

In depth, this report provides the following –
– Provides the detailed analysis of drugs examined by the European Medi¬cines Agency (EMA). The centralized procedure is mandatory for all New Active Substances, as well as Biosimilar drugs and certain generics depending on their therapeutic category.
– Analyzes propensity to outsource by dosage form, sponsor type, nature of API and special handling requirements. In addition, it includes information on product approvals, which have utilized formulation technologies such as amorphous solid dispersion (ASD), hot melt extrusion (HME) and jet milling.
– Helps for CMO executives and strategic decision-makers who seriously follow the global CMO industry, including dose and API manufacturers.

Reasons to buy

This report is required reading for –
– CMO executives and strategic decision-makers who seriously follow the global CMO industry, including dose and API manufacturers.
– Bio/Pharma sponsors that buy contract manufacturing services and need to understand contract manufacturing industry drivers.

Filed in: Pharmaceutical, Pharmaceuticals and Healthcare
Publisher : GlobalData
More Reports
Title Price Buy Now

Pharmaceutical Packaging Equipment Market by Product (Aseptic Packaging, Blister, Strip, Bottle, Tube, Carton, Case Packer, Wrapping Machine, Palletizing, Labeling & Serialization), Type (Tablet, Powder, Cream, Syrup, Aerosol), Region – Global Forecast to 2025

The pharmaceutical packaging equipment market is expected to grow at a CAGR of 7.4% in the forecast period. The global pharmaceutical packaging equipment market size is projected to reach USD 10.4 billion by 2025 from USD 7.3 billion in 2020, at a CAGR of 7.4% from 2020 to 2025. The growth of the market is driven by the rapidly growing generic & biopharmaceutical markets, growth in OTC drug sales, rising need for flexible & integrated packaging equipment, increased offshore manufacturing in the pharmaceuticals market, and the introduction of regulatory standards on packaging & stringent norms against counterfeiting. However, factors such as the adoption of refurbished packaging equipment and the high cost of packaging equipment are expected to restrain market growth to a cer......
$4950

Meningococcal Vaccines – Global Drug Forecast and Market Analysis to 2029

Meningococcal Vaccines - Global Drug Forecast and Market Analysis to 2029 Summary Meningococcal disease is an infection caused by Neisseria meningitidis bacteria, and, although relatively rare, is widely feared because of its high mortality rate even in otherwise healthy individuals. Serogroups A, B, C, W, and Y are the most common meningococcal types in the nine major markets (9MM) covered in this report (US, France, Germany, Italy, Spain, UK, Argentina, Brazil, and China), and immunization of high-risk groups such as infants and adolescents provides the best protection against the infection. Immunization with conjugated meningococcal serogroup C (MenC) is routinely recommended for infants in the 5EU and Brazil, and immunization against serogroup ACWY (MenACWY vaccines) is recommended i......
$10995

Invasive Meningococcal Disease – Epidemiology Forecast to 2029

Invasive Meningococcal Disease - Epidemiology Forecast to 2029 Summary Invasive meningococcal disease (IMD) is a life-threatening condition caused by the bacterium Neisseria meningitidis (N. meningitidis). N. meningitidis is an encapsulated gram-negative bacterium that exists without complication in roughly 5-11% of adults and up to 25% of adolescents. However, if the bacterium moves beyond the nasopharynx and invades body tissue, serious illness can arise, usually in the form of meningitis or septicemia. Symptoms of disease can include fever, headache, stiff neck, nausea, photophobia, and fatigue, among others. The bacterium is spread by respiratory droplets through close or prolonged contact with an infected person and is not as contagious as the common cold or flu. In 2019, there wer......
$3995

Ulcerative Colitis – Epidemiology Forecast to 2029

Ulcerative Colitis - Epidemiology Forecast to 2029 Summary Ulcerative colitis (UC) is an inflammatory bowel disease (IBD) characterized by chronic inflammation of the large intestine and the rectum. The inflammation occurs only in the innermost layer of the lining of the intestine. In UC, ulcers develop on the surface of the bowel lining; these may bleed and produce mucus. If the inflammation is confined to rectum, it is called proctitis (Crohn's and Colitis Foundation of America, 2014; Crohn's and Colitis UK, 2019). UC can occur at any age, though most people are diagnosed in their mid-thirties. Men and women are equally likely to be affected, but older men are more likely to be diagnosed than older women. GlobalData epidemiologists utilized historical data obtained from peer-reviewed......
$3995

Contract Dose Manufacturing Industry by the Numbers – Composition, Size, Market Share and Outlook – 2020 Edition

Contract Dose Manufacturing Industry by the Numbers - Composition, Size, Market Share and Outlook - 2020 Edition Summary This expert trend report is a comprehensive look at the finished dose contract manufacturing landscape in 2020, including analysis of dose CMO M&A activity, market size and share. It is a critical source for strategic planning efforts and will improve understanding of crucial components of the supply chain that will provide insights for supplier selection and management. This report gives an important expert quantitative analysis on the contract dose manufacturing industry. Findings are based on the industry's most comprehensive database of the dose CMO industry (GlobalData's Pharma Intelligence Center Contract Service Providers Database) this analysis is driven by a ......
$4995

Egypt Healthcare, Regulatory and Reimbursement Landscape – CountryFocus

Egypt Healthcare, Regulatory and Reimbursement Landscape - CountryFocus Summary GlobalData, the industry analysis specialist, has released its latest report, "Egypt Healthcare, Regulatory and Reimbursement Landscape - CountryFocus". The report is an essential source of information on analysis of the healthcare, regulatory and reimbursement landscape in Egypt. It identifies the key trends in the country's healthcare market and provides insights into its demographic, regulatory and reimbursement landscape, and healthcare infrastructure. Most importantly, the report provides valuable insights into the trends and segmentation of its pharmaceutical and medical device markets. It uses data and information sourced from proprietary databases, secondary research, and in-house analysis by GlobalDa......
$1995

Coronavirus Disease 2019 (COVID-19) Impact on Telemedicine, a Physician Perspective

Coronavirus Disease 2019 (COVID-19) Impact on Telemedicine, a Physician Perspective Summary Telemedicine is the use of electronic communication for the delivery of remote clinical care. It has been recognized as a critical strategy during the ongoing coronavirus disease 2019 (COVID-19) pandemic to limit the risk of person-to-person transmission of the virus as social distancing has become the norm. It is widely anticipated that COVID-19 may be the tipping point for telemedicine as the full potential of the technology is increasingly realized by patients, healthcare systems, and payers. As a result of the pandemic, regulations and policies governing reimbursement and use of telemedicine have changed significantly, leading to expanded access and an unprecedented demand for these services.......
$1495

Greece Healthcare, Regulatory and Reimbursement Landscape – CountryFocus

Greece Healthcare, Regulatory and Reimbursement Landscape - CountryFocus Summary GlobalData, the industry analysis specialist, has released its latest report: "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Greece". The report is an essential source of information on analysis of the healthcare, regulatory and reimbursement landscape in Greece. It identifies the key trends in the country's healthcare market and provides insights into its demographic, regulatory and reimbursement landscape, and healthcare infrastructure. Most importantly, the report provides valuable insights into the trends and segmentation of its pharmaceutical and medical device markets. It uses data and information sourced from proprietary databases, secondary research, and in-house analysis by Glob......
$1995

Malnutrition – Global Clinical Trials Review, H2, 2020

Malnutrition - Global Clinical Trials Review, H2, 2020 Summary GlobalData's clinical trial report, "Malnutrition Global Clinical Trials Review, H2, 2020" provides an overview of Malnutrition Clinical trials scenario. This report provides top line data relating to the clinical trials on Malnutrition. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma - Clinical trials database. Clinical trials......
$2500

Mania Disease – Global Clinical Trials Review, H2, 2020

Mania Disease - Global Clinical Trials Review, H2, 2020 Summary GlobalData's clinical trial report, "Mania Disease - Global Clinical Trials Review, H2, 2020" provides an overview of Mania Clinical trials scenario. This report provides top line data relating to the clinical trials on Mania. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma - Clinical trials database. Clinical trials are colla......
$2500
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy